- Molecular NameDeferiprone
- SynonymNA
- Weight139.154
- Drugbank_IDN/A
- ACS_NO30652-11-0
- Show 3D model
- LogP (experiment)-0.68
- LogP (predicted, AB/LogP v2.0)-0.6
- pka3.5
- LogD (pH=7, predicted)-0.61
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.15
- LogSw (predicted, AB/LogsW2.0)29.51
- Sw (mg/ml) (predicted, ACD/Labs)9.81
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds0
- TPSA40.54
- StatusN/A
- AdministrationN/A
- PharmacologyAn oral drug that chelates iron and is used to treat thalassaemia major.
- Absorption_valueN/A
- Absorption (description)Deferiprone is rapidly absorbed
- Caco_2N/A
- BioavailabilityN/A
- Protein binding33.7
- Volume of distribution (VD)Steady state, 1.55 to 1.73 L/kg; healthy volunteers, 72.8 L/kg; patients with β-thalassemia, 115.1 L/kg.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMore than 85% of an administered dose is metabolised in the liver by glucuronidation to a conjugate lacking chelating properties.
- Half life1~2.5 h
- ExcretionDeferiprone is excreted mainly in urine (approx. 80% recovered) as the parent drug, its conjugate and bound to iron. Only a small proportion of the drug is found unchanged in urine within 24 h. Excretion of the glucuronide is slower than that of the parent drug. Other metabolites include an O-methyl metabolite, 2-hydroxylmethyl metabolite and its glucuronide.
- Urinary ExcretionN/A
- CleranceHealthy volunteers, 34.8 L/h; patients with β-thalassemia, 39.6 L/h.
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A